Subscription businesses live or die on a number they rarely disclose: how many customers are angry enough to call their bank. For Hims & Hers Health, that number just became public, and not on the company’s terms.
Hims & Hers was put on notice by Visa for excessive customer complaints in its weight-loss subscription business, with the telehealth company enrolled in Visa’s Acquirer Monitoring Program after a surge of credit card disputes in July, according to internal documents reviewed by Bloomberg. The weight-loss business generated 75% of Hims’ credit card disputes. Membership starts at $39 for the first month, then rises to $149, with automatic renewals; prescription drugs are billed separately. The company’s response was characteristic: a spokesperson told Bloomberg it has seen “a relatively small number of disputed charges” and that checkout is clear about membership and medication costs.
Why Dispute Rates Are the Thesis, Not Just the News
The investment question inside this story has nothing to do with the nearly $75,000 bill. Hims must bring its dispute rate below 1.5% of transactions and hold it there for three consecutive months to exit the program, with each dispute triggering an $8 surcharge in the meantime, according to the Bloomberg report. The direct cost is trivial against a company guiding for $3.1 billion to $3.3 billion in full-year 2026 revenue. What matters is what a chargeback spike tells you about the GLP-1 book that earnings calls do not.
Investors tend to watch these episodes closely because subscription revenue looks predictable only as long as customers stay happy enough not to dispute charges, and as long as the payment rails keep running smoothly. Hims has built its valuation on the premise that weight-loss subscribers are sticky. Chargebacks are what customers file when they feel they cannot cancel any other way. The rate of those filings is therefore a cleaner, real-time read on retention quality than whatever cohort language management chooses at the next earnings call.
When Visa flags a merchant, the pressure usually flows through the whole payments stack. For Hims, that can mean near-term margin pressure from dispute fees and extra support costs, plus a softer hit if stricter billing and refund rules lower conversions. Hims is reportedly considering clearer notifications about upcoming charges to prevent customers from being caught off guard. That is a concession, even if management will not frame it that way.
A Compounding Regulatory File
The Visa action does not arrive in isolation. It intensified pressure on Hims just weeks after the FTC, Utah, and Los Angeles County sued the company over its billing, cancellation, and data practices, with regulators alleging Hims deceived consumers about billing and cancellation and shared sensitive health information with third parties despite privacy promises.
Separately, Hims has disclosed that the FDA has taken a public stance against mass-marketed, non-FDA-approved compounded GLP-1 drugs, and the company has said the SEC opened an investigation in February 2026 into the company’s statements and disclosures related to compounded semaglutide and related business relationships.
Barclays trimmed its price target on HIMS to $35 from $39 on August 21, reflecting growing concern over the company’s billing and cancellation practices. Shares closed Monday at $31.02, down 8.3% from the previous session.
Bull Case, Bear Case
The bull argument is straightforward: Q2 2026 revenue came in at $753.2 million, up 38% year-over-year, with subscribers growing to 2.891 million, up 19%. The weight-loss category is genuinely large, and the Novo Nordisk collaboration gives Hims access to branded GLP-1s like Wegovy and Ozempic on its platform. If chargeback rates normalize quickly, the monitoring program becomes a footnote.
The bear case is that chargebacks are a lagging signal. They reflect billing experiences from weeks or months prior. If July’s dispute surge reflects structural confusion about how Hims prices and auto-renews its weight-loss memberships, the fix requires more than clearer notification emails. It may require pricing and cancellation changes that pressure the revenue model itself. That is the scenario the stock has not priced.
What to Watch
The exit condition is explicit: three consecutive months below 1.5% dispute rate. Whether Hims achieves that by Q4, and how it does so, will tell investors more about the true quality of its GLP-1 subscriber base than any metric the company voluntarily discloses. Watch Q3 guidance commentary on cancellation policy changes, and watch whether the FTC lawsuit advances to discovery. Either development would clarify whether this is a billing-process problem or a retention problem. They are not the same thing, and the market is currently treating them as if it cannot tell the difference.